Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 15, 718 - 722 (2009)
doi:10.1038/nm0709-718
Outpacing Cancer
Kirsten Dorans1
- Kirsten Dorans is an assistant editor at Lab Animal, a Nature Publishing Group publication, based in New York.
Abstract
In the late 1990s the drug gefitinib became a new tool in treating the most common type of lung cancer, called non–small cell lung cancer. But doctors found that even with continued gefitinib treatment, some patients experienced a cancer relapse within a year. For the past several years, researchers have been working to uncover why these patients lost sensitivity to gefitinib and seeking how to overcome resistance to the drug. Kirsten Dorans reports on the strategies scientists are developing to outpace continually evolving cancer.
It was early February 2002 and William Pao was working as a fellow in the lung cancer clinic of the Memorial Sloan-Kettering Cancer Center in New York. A woman in her mid-50s from upstate New York came in for an appointment at the clinic.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cancer Broken genes in solid tumoursNature News and Views (02 Aug 2007)
Where lies the blame for resistance?tumor or host?Nature Medicine News and Views (01 Oct 2007)
